MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells

被引:55
作者
Yu, Dianke [1 ]
Green, Bridgett [1 ]
Tolleson, William H. [1 ]
Jin, Yaqiong [2 ]
Mei, Nan [1 ]
Guo, Yongli [2 ]
Deng, Helen [3 ]
Pogribny, Igor [1 ]
Ning, Baitang [1 ]
机构
[1] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA
[2] Capital Med Univ, Beijing Pediat Res Inst, Beijing Childrens Hosp, Beijing Key Lab Pediat Dis Otolaryngol Head & Nec, Beijing 100045, Peoples R China
[3] Arkansas Dept Hlth, Little Rock, AR 72205 USA
关键词
hsa-miR-29a-3p; CYP2C19; Drug metabolizing enzymes; Pharmacogenomics; Inter-individual variability; microRNA; DRUG-METABOLISM; GENE-EXPRESSION; ASSOCIATION; RIFAMPICIN; RECEPTOR; IDENTIFICATION; POLYMORPHISM; INDUCTION; TRANSPORT; GENOTYPE;
D O I
10.1016/j.bcp.2015.08.094
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P450 2C19 (CYP2C19) is involved in the metabolism of many drugs. Extensive studies have demonstrated that genetic variants and endogenous and environmental factors play important roles in the expression of CYP2C19. However, the role of microRNAs (miRNAs) in controlling CYP2C19 expression has not been investigated completely. In the present study, we performed in silico analysis to rank putative miRNA/CYP2C19 hybrids with regards to the predicted stabilities of their duplexes and then we applied a series of biochemical and molecular assays to elucidate the underlying functional mechanisms for the regulation of CYP2C19 by miRNAs. In silico analysis indicated that hsa-miR-23a-3p and hsa-miR-29a-3p target the coding region of CYP2C19 with hybrid stabilities of -27.5 kcal/mol and -23.3 kcal/mol, respectively. RNA electrophoresis mobility shift assays showed that both hsa-miR-23a-3p and hsa-miR-29a-3p miRNAs were able to bind directly to their cognate targets in the CYP2C19 transcript. Further, a significant inverse correlation was found between chemically-induced up-regulation of hsa-miR-29a-3p and CYP2C19 expression in HepaRG cells. In addition, inverse correlations were also observed in human liver tissue samples between the level of CYP2C19 mRNA expression and both hsa-miR-23a-3p and hsa-miR-29a-3p levels. All these results demonstrated the suppressing role of hsa-miR-29a-3p on CYP2C19 expression. Published by Elsevier Inc.
引用
收藏
页码:215 / 223
页数:9
相关论文
共 38 条
[1]   MicroRNA-602 and MicroRNA-608 Regulate Sonic Hedgehog Expression via Target Sites in the Coding Region in Human Chondrocytes [J].
Akhtar, Nahid ;
Makki, Mohammad S. ;
Haqqi, Tariq M. .
ARTHRITIS & RHEUMATOLOGY, 2015, 67 (02) :423-434
[2]   Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter [J].
Chen, YP ;
Ferguson, SS ;
Negishi, M ;
Goldstein, JA .
MOLECULAR PHARMACOLOGY, 2003, 64 (02) :316-324
[3]   Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor [J].
Chen, YP ;
Ferguson, SS ;
Negishi, M ;
Goldstein, JA .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (02) :495-501
[4]   Metabolism of profenofos to 4-bromo-2-chlorophenol, a specific and sensitive exposure biomarker [J].
Dadson, Oswald A. ;
Ellison, Corie A. ;
Singleton, Steven T. ;
Chi, Lai-Har ;
McGarrigle, Barbara P. ;
Lein, Pamela J. ;
Farahat, Fayssal M. ;
Farahat, Taghreed ;
Olson, James R. .
TOXICOLOGY, 2013, 306 :35-39
[5]  
DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594
[6]   Clinical significance of the cytochrome P4502C19 genetic polymorphism [J].
Desta, Z ;
Zhao, XJ ;
Shin, JG ;
Flockhart, DA .
CLINICAL PHARMACOKINETICS, 2002, 41 (12) :913-958
[7]   The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to M1 mutation of CYP2C19 and gene dose [J].
Feng, HJ ;
Huang, SL ;
Wang, W ;
Zhou, HH .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (01) :27-29
[8]   Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations [J].
Goldstein, JA ;
Ishizaki, T ;
Chiba, K ;
deMorais, SMF ;
Bell, D ;
Krahn, PM ;
Evans, DAP .
PHARMACOGENETICS, 1997, 7 (01) :59-64
[9]   THE MECHANISM OF THE WARFARIN-RIFAMPIN DRUG-INTERACTION IN HUMANS [J].
HEIMARK, LD ;
GIBALDI, M ;
TRAGER, WF ;
OREILLY, RA ;
GOULART, DA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 42 (04) :388-394
[10]  
Helsby Nuala Ann, 2012, Frontiers in Genetics, V3, P206, DOI 10.3389/fgene.2012.00206